Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: lostmymoney who wrote (16796)	9/29/1999 12:29:00 PM
From: John R Resseger	Read Replies (1) \| Respond to of 29382

I've been involved in this stock for four years maybe. I've read and reread their stuff. I just found this important tidbit that has been there all along! "...Antex vaccines that prevent infection before bacteria can penetrate tissue." Platform Technologies To develop vaccines against common infections, Antex Biologics has developed two unique technologies: ART (Adhesin-Receptor Technology) and NST (Nutriment Signal Transduction). While vaccines typically provide protection after bacteria enter the body, these new technologies are the platform for Antex vaccines that prevent infection before bacteria can penetrate tissue. The vaccines developed with these technologies could be administered orally or nasally rather than by injection. Oral administration makes vaccination less expensive and easier to receive for patients, and significantly lowers the chance of adverse reactions.